2. Academic Validation
  3. C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization

C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization

  • Bioorg Med Chem Lett. 2010 Mar 1;20(5):1569-72. doi: 10.1016/j.bmcl.2010.01.075.
Ralph P Robinson 1,  Vincent Mascitti,  Carine M Boustany-Kari,  Christopher L Carr,  Patrick M Foley,  Emi Kimoto,  Michael T Leininger,  Andre Lowe,  Michelle K Klenotic,  James I Macdonald,  Robert J Maguire,  Victoria M Masterson,  Tristan S Maurer,  Zhuang Miao,  Jigna D Patel,  Cathy Préville,  Matthew R Reese,  Li She,  Claire M Steppan,  Benjamin A Thuma,  Tong Zhu
Affiliations

Affiliation

  • 1 Pfizer Global Research & Development, Groton Laboratories Eastern Point Rd, Groton, CT 06340, United States. ralph.p.robinson@pfizer.com
PMID: 20149653 DOI: 10.1016/j.bmcl.2010.01.075
Abstract

Modifications to the sugar portion of C-aryl glycoside sodium glucose transporter 2 (SGLT2) inhibitors were explored, including systematic deletion and modification of each of the glycoside hydroxyl groups. Based on results showing activity to be quite tolerant of structural change at the C-5 position, a series of novel C-5 spiro analogues was prepared. Some of these analogues exhibit low nanomolar potency versus SGLT2 and promote urinary glucose excretion (UGE) in rats. However, due to sub-optimal pharmacokinetic parameters (in particular half-life), predicted human doses did not meet criteria for further advancement.

Figures
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验，部分功能也使用 Cookies 帮助我们更好地理解您的需求，为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问，请阅读我们的《隐私声明》。

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z